Pharmaceuticals

"Lactobacillus Rhamnosus L34": A Native Probiotic That Reduces Inflammation in Patients with Chronic Kidney Disease

BANGKOK, April 8, 2026 /PRNewswire/ -- Researchers from the Faculty of Medicine at Chulalongkorn University have identified a native probiotic strain, Lactobacillus rhamnosus L34, that may help reduce inflammation and toxin buildup in pa...

2026-04-08 16:56 4201

Everest Medicines Signs Share Purchase Agreement with Hasten Biopharmaceuticals (Asia) Limited

* Accelerates Asia Pacific expansion by acquiring a ready-built regional commercial platform with 14 marketed chronic disease products * Aggregate consideration of USD250,000,000 (approximately RMB1,721,650,000), payable in three installments * Delivers near-term revenue and profitability wi...

2026-04-08 10:21 9557

Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development

-Fixed-dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective monotherapies in a head-to-head study. The fixed dose combination had excellent oral bioavailability, drug exposure and a half-lif...

2026-04-07 19:00 6418

Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1 2026). Q1 2026 Highlights * Q1 2026 unaudited ...

2026-04-07 06:57 6625

TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions

Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data Collaboration will expand Regeneron's world-leading genomic and proteomic EHR-linked database Growing database will continu...

2026-04-03 04:34 5764

Lupin Completes Acquisition of VISUfarma

MUMBAI, India and LONDON and ROME and ZUG, Switzerland, April 2, 2026 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced the completion of its acquisition of VISUfarma B.V. (VISUfarma), a leading European specialty...

2026-04-02 15:00 4322

Telix Appoints David Gill as Non-Executive Director

MELBOURNE, Australia and INDIANAPOLIS, April 2, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May...

2026-04-02 06:59 5184

Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint

SUZHOU, China, April 1, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceu...

2026-04-01 22:44 5667

NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development

PRINCETON, N.J. and TOKYO, April 1, 2026 /PRNewswire/ -- NJ Bio, Inc. ("NJ Bio"), a leading provider of integrated drug discovery and development services and Ajinomoto Bio‑Pharma Services ("Aji Bio‑Pharma"), a leading provider of biopharmaceutical manufacturing services and platform technologies...

2026-04-01 07:00 4373

Dalton Pharma Services Expands Aseptic Powder Fill-Finish Capacity with RoboFil™ system in Toronto

A fully automated aseptic fill-finish platform delivers greater speed, flexibility, and quality for the manufacturing of clinical supplies and commercial products. TORONTO, March 31, 2026 /PRNewswire/ -- Dalton Pharma Services today announced the successful installation of its RoboFil™ aseptic p...

2026-03-31 22:00 3253

Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2

BEIJING and BRIDGEWATER, N.J., March 31, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (SSE: 603087) today announced that two pivotal phase 3 clinical trials, SUPER-1 and SUPER-2, evaluating investigative once-weekly insulin GZR4 Injection, have successfully met their pre-specified primary endpo...

2026-03-31 21:50 3769

Inaugural Rabies in Asia Conference to Be Held in Kuching

KUCHING, Malaysia, March 31, 2026 /PRNewswire/ -- Place Borneo Sdn Bhd, in collaboration with the Department of Veterinary Services Sarawak (DVSS), will host the 1st Rabies in Asia (RIA) 2026 in conjunction with the 5th Rabies in Borneo (RIB) 2026, taking place 29 September to 1 October 2026 at t...

2026-03-31 20:31 3539

3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone

SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc. (01530.HK ) today released its 2025 annual results announcement. Fueled by the dual core engines of breakthroughs in innovative R&D and strategic global collaboration, the company delivered a high-quality performance with bot...

2026-03-31 20:13 6391

SirPAD: Primary Results confirm the safety and efficacy of Sirolimus Coated Balloon in PAD

TAMPA, Fla., March 31, 2026 /PRNewswire/ -- Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the presentation of the world's largest randomised controlled trial of a Sirolimus-coa...

2026-03-31 16:27 3599

Qyuns Therapeutics-B (02509) 2025 Revenue Surges Over 4-Fold; Adjusted Profit Reaches Approximately RMB356 Million, Turning a Profit Year-on-Year

TAIZHOU, China, March 30, 2026 /PRNewswire/ -- Qyuns Therapeutics-B (02509) announced its 2025 annual results. Revenue amounted to approximately RMB807 million, representing a 4.08-fold year-on-year increase. Gross profit reached approximately RMB714 million, a 6.75-fold increase year-on-year. Pr...

2026-03-30 12:39 7975

Organon accelerates Women's Health progress across Asia Pacific with 2026 Her Health Grants

SYDNEY, March 30, 2026 /PRNewswire/ -- Organon Asia Pacific Cluster today announced the 2026 Her Health Grant recipients for the Asia Pacific region, marking a significant milestone in efforts to strengthen and expand women's health initiatives across the region. The Her Health Grants are design...

2026-03-30 06:31 4170

Chula, Thai Red Cross Society Partner to Bring "SALYWA" Artificial Saliva to Patients

BANGKOK, March 26, 2026 /PRNewswire/ -- Chulalongkorn University , in collaboration with the Thai Red Cross Society  and Specialty Innovation Co., Ltd., held a press conference announcing the licensing agreement for research utilization a...

2026-03-26 18:04 4657

Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights

SUZHOU, China, March 26, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2025 and highlighted recent business progress. Key Highlights * KN026 (Anbenitamab) achieved robust PFS and OS benefits in second- or third-lin...

2026-03-26 13:13 6991

BIOTRONIK Leaps Forward with Next‑Generation Leadless Pacing

* International BIO-LivIQ Study Will Generate Evidence for Global LivIQ Leadless Pacemaker Approvals * Far-Field Sensing and AV-Synchronous Pacing Performance Will be Validated by Real World Clinical Data BERLIN, March 24, 2026 /PRNewswire/ -- BIOTRONIK today announced the initiation of its g...

2026-03-24 22:06 2974

Kelun-Biotech Receives IND Approval for SKB103, a Novel TAA-PD-L1 Bispecific ADC

CHENGDU, China, March 24, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that the Investigational New Drug (IND) application for SKB103, its self-developed novel bispecific antibody-drug conjugate with combined T...

2026-03-24 17:24 4283
12345678 ... 185

Week's Top Stories